Related Videos
Video
Head and Neck Study Presented by Robert Haddad, MD
Dana-Farber's Dr. Robert Haddad says research shows the combination of a PD1 with anti-LAG3 +/- anti-TIM3 does not improve outcomes in metastatic disease, raising the question of whether to look at this combo earlier, in the neoadjuvant setting.
Video
Robert Haddad, MD Discusses Head and Neck Cancer Research at AACR24
Important IMvoke010 trial could shape future research in immunotherapy in locally advanced head & neck cancer after results of 1st phase III study in adjuvant therapy don't meet event-free survival endpoint. Dana-Farber's Robert Haddad, ...